Cybin Inc | Company Profile
NEO : CYBN
Latest Sector Updates
Cybin aims to deliver powerful and effective new psychedelic therapies for those with mental health conditions. Their ‘3 pillars strategy’ consists of novel drug discovery, proprietary drug delivery systems and an innovative treatment regimen.
Cybin has multiple patent filings covering a wide range of novel psychedelic compounds and novel drug delivery platforms. Their most advanced clinical trials are Phase IIA and IIB trails for sublingual psilocybin in patients with Major Depressive Disorder (MDD).
In June 2020 Cybin carried out a reverse takeover to list on the NEO exchange and raised C$45m in an upsized, oversubscribed raise. The company raised just over C$34m in a further round in February 2021 and on March 8th listed on the OTCQB Venture Market.
Stock information
Contact Information
Latest Cybin News
Cybin Provides 2021 Year End Summary
Cybin Confirms Scientific Advice Meeting with UK Medical and Healthcare Products Regulatory Agency for Lead Candidate CYB003 for the Treatment of Major Depressive Disorder and Alcohol Use Disorder
Cybin Announces FDA Investigational New Drug and Institutional Review Board Approvals for a Co-Funded Phase 2 Clinical Trial to Treat Frontline Clinicians Experiencing COVID-Related Distress
Cybin Awards Grant for Psychedelic Treatment Clinic at Lenox Hill Hospital to Benefit Underserved Communities
Cybin Inc. Reports its Second Quarter Financial Results and Recent Business Highlights
